Predictive Cancer Biomarkers: Current Practice and Future Challenges

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F19%3A73594731" target="_blank" >RIV/61989592:15110/19:73594731 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Predictive Cancer Biomarkers: Current Practice and Future Challenges
Original language description
Personalized cancer treatment became a standard approach in the treatment of human cancers in twenty-first century. Among predictive cancer biomarkers, the estrogen and progesterone receptors (ER, PR) have the longest history: they have been used in the clinic to predict responses to endocrine therapy in breast cancer for over 40 years. Similarly, the HER2 receptor status measurements have been used clinically to predict responsiveness to trastuzumab (Herceptin) in breast cancers for over 15 years. The success of the personalized approach in oncology has multiple determinants. Among others, most prominent is the nature of the disease, which is multifactorial in principle and requires patient stratification in order to select the most appropriate treatment to achieve meaningful therapeutic benefit and substantiate the relative high cost of therapy.
Czech name
—
Czech description
—

Project
<a href="/en/project/LO1304" target="_blank" >LO1304: Support of suistainability of the Institute of Molecular and Translational Medicine</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)